Nature Communications (Apr 2020)
Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway
- Gregory M. LaMonte,
- Frances Rocamora,
- Danushka S. Marapana,
- Nina F. Gnädig,
- Sabine Ottilie,
- Madeline R. Luth,
- Tilla S. Worgall,
- Gregory M. Goldgof,
- Roxanne Mohunlal,
- T. R. Santha Kumar,
- Jennifer K. Thompson,
- Edgar Vigil,
- Jennifer Yang,
- Dylan Hutson,
- Trevor Johnson,
- Jianbo Huang,
- Roy M. Williams,
- Bing Yu Zou,
- Andrea L. Cheung,
- Prianka Kumar,
- Timothy J. Egan,
- Marcus C. S. Lee,
- Dionicio Siegel,
- Alan F. Cowman,
- David A. Fidock,
- Elizabeth A. Winzeler
Affiliations
- Gregory M. LaMonte
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Frances Rocamora
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Danushka S. Marapana
- Division of Infection and Immunity, Walter and Eliza Hall Institute for Medical Research
- Nina F. Gnädig
- Department of Microbiology & Immunology, Columbia University Irving Medical Center
- Sabine Ottilie
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Madeline R. Luth
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Tilla S. Worgall
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center
- Gregory M. Goldgof
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Roxanne Mohunlal
- Department of Microbiology & Immunology, Columbia University Irving Medical Center
- T. R. Santha Kumar
- Department of Microbiology & Immunology, Columbia University Irving Medical Center
- Jennifer K. Thompson
- Division of Infection and Immunity, Walter and Eliza Hall Institute for Medical Research
- Edgar Vigil
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Jennifer Yang
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Dylan Hutson
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Trevor Johnson
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego
- Jianbo Huang
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego
- Roy M. Williams
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Bing Yu Zou
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Andrea L. Cheung
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Prianka Kumar
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Timothy J. Egan
- Department of Chemistry, University of Cape Town
- Marcus C. S. Lee
- Parasites and Microbes Programme, Wellcome Sanger Institute
- Dionicio Siegel
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego
- Alan F. Cowman
- Division of Infection and Immunity, Walter and Eliza Hall Institute for Medical Research
- David A. Fidock
- Department of Microbiology & Immunology, Columbia University Irving Medical Center
- Elizabeth A. Winzeler
- Department of Pediatrics, School of Medicine, University of California, San Diego
- DOI
- https://doi.org/10.1038/s41467-020-15440-4
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
Imidazolopiperazines (IZPs) are a class of compounds under clinical development for malaria, but their mechanism of action is unclear. Here, the authors show that IZPs inhibit the parasite’s secretory pathway, affecting protein trafficking and export.
